Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
Table of Contents Commonly Used Injection Sites for Retatrutide Retatrutide is injected subcutaneously into the abdomen (at least 5 cm from the navel), the anterolateral mid-thigh, or the outer upper arm, with all site guidance governed by the clinical trial protocol
Serious but less common risks include pancreatitis, gallbladder disease, low blood sugar (particularly if used with diabetes medications), and kidney problems
Insufficient protein in your diet can weaken hair, potentially leading to hair loss
Annual blood tests including serum B12, full blood count, ferritin, vitamin D, and folate are recommended as a minimum for long-term post-bariatric monitoring
US$ 25.30
US$ 27.97
US$ 28.20
US$ 25.40
US$ 25.37
US$ 24.78
US$ 23.61
US$ 28.25
